Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Bodkin, J. A. Articles by Cole, J. O. Search for Related Content PubMed Citation Articles by Bodkin, J. A. Articles by Cole, J. O. Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders Other Somatic Therapy

Double-Blind, Placebo-Controlled, Multicenter Trial of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Outpatients With Schizophrenia

OBJECTIVE: The authors’ goal was to test the efficacy of selegiline augmentation of antipsychotic medication in outpatients with schizophrenia who had negative symptoms of moderate or greater severity. METHOD: A 12-week, double-blind, placebo-controlled, multicenter trial of oral selegiline augmentation of antipsychotic medication was carried out. Outpatients were chosen who did not manifest severe positive symptoms at baseline, who did not meet criteria for coexisting major depression, and who had been maintained on a stable regimen of antipsychotic medication. RESULTS: Negative symptoms were found to be significantly more improved in the patients who received selegiline, and global improvement scores reinforced the impression that selegiline augmentation was beneficial. CONCLUSIONS: These findings support further investigation of low-dose selegiline augmentation of antipsychotic medication in outpatients with schizophrenia who have at least a moderate burden of negative symptoms.

This article has been cited by other articles:

				R. W. Buchanan Persistent Negative Symptoms in Schizophrenia: An Overview Schizophr Bull, July 1, 2007; 33(4): 1013 - 1022. [Abstract] [Full Text] [PDF]

				K. D Fohey, R. Hieber, and L. A. Nelson The Role of Selegiline in the Treatment of Negative Symptoms Associated with Schizophrenia Ann. Pharmacother., May 1, 2007; 41(5): 851 - 856. [Abstract] [Full Text] [PDF]

				K. N Sokolski and B. J Brown Quetiapine for Insomnia Associated with Refractory Depression Exacerbated by Phenelzine Ann. Pharmacother., March 1, 2006; 40(3): 567 - 570. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us